Shilpa Medicare’s arm completes GMP inspection from Brazilian regulatory authority
The audit was carried out between June 30 to July 4, 2025 and has been concluded with No Critical and No Major observations
Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences’ Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. The audit was carried out between June 30 to July 4, 2025 and has been concluded with No Critical and No Major observations.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
